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A Ab bs st tr ra ac ct t
Astrocytes mediate either constriction or dilation of local brain arterioles in response to synaptic
activity. Recent work indicates that the directionality of this response may be dictated by ambient
oxygen levels.
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In the brain, astrocyte processes are arranged in coordinated
non-overlapping spatial domains such that the vast majority
of the surface area of cerebral arterioles and capillaries is
contacted by astrocyte endfeet [1]. This makes astrocytes
uniquely well positioned to send vasoactive signals to the
blood-brain barrier. Several studies now present a consensus
view that astrocytes respond to input from glutamate-
producing (glutamatergic) neurons by increasing intra-
cellular Ca2+, phospholipase A2 (PLA2)-mediated arachi-
donic acid formation, and metabolism of arachidonic acid to
produce either vasodilatory [2-6] or vasoconstrictor [5,7]
metabolites. The conditions under which astrocytes elicit
vasodilation or vasoconstriction have remained largely con-
fusing, as either domination of one effect over the other
[2,4,7,8] or both effects have been reported in various tissue
slice models [5]. In addition, it has not been clear how
astrocyte participation in functional or hypoxic hyperemia
(an increase in blood flow) fits with the involvement of meta-
bolic mediators such as adenosine, lactate, H+, K+ and CO2,
all of which have been implicated in this critical neuro-
physiological process [9,10]. A recent report from the
laboratory of Brian MacVicar (Gordon et al. [11]) signifi-
cantly clarifies both these issues. Here we discuss this work
and give an overview of the multiple pathways by which
astrocytes influence neuronal energy supply.
D Do o   a as st tr ro oc cy yt te es s   c ca au us se e   v va as so od di il la at ti io on n   o or r   v va as so oc co on ns st tr ri ic ct ti io on n? ?
Zonta et al. [2] provided the first direct demonstration that
astrocytes in brain slices sense increased levels of glutamate
(due to neuronal activity) via metabotropic glutamate recep-
tors (mGluRs) and respond with an increase in endfoot Ca2+,
activation of PLA2 and metabolism of arachidonic acid by
COX-1 to produce vasodilatory prostaglandins (probably
PGE2) [2,12]. Subsequent studies confirmed a vasoactive
role for astrocyte mGluR activation and Ca2+ elevation, but
reported vasoconstriction rather than vasodilation [7];
constriction was attributed to PLA2-mediated arachidonic
acid production by astrocytes, followed by diffusion of the
arachidonic acid to smooth muscle and subsequent metabo-
lism by cytochrome P450 4A (ω-hydroxylase) to 20-hydroxy-
eicosatetraenoic acid (20-HETE). The clear objective left in
the wake of these initial papers was to determine whether
constriction or dilation was the ‘physiological’ response to
astrocyte activation. Dilation required the presence of a
nitric oxide synthase (NOS) inhibitor or other pre-
constrictor [2,5-7], and was converted to constriction when
NOS inhibitors were excluded [7], raising the possibility that
dilations could only be produced by artificial enhancement
of baseline vascular tone. On the other hand, constriction
was intuitively less attractive as the natural response to
increased neuronal work. More recent in vivo studies inanesthetized mice provided strong support for dilation by
showing that increased astrocyte Ca2+ levels produced only
COX-1-dependent vasodilations and corresponding local
increases in blood flow [3]. This was a crucial observation as
it verified astrocyte-mediated control of cerebral micro-
circulation - specifically dilations - outside the brain slice
model, which can be critiqued as non-physiological due to
the lack of arterial pressurization. It was also shown recently
that inhibition of 20-HETE synthesis failed to affect inte-
grated somatosensory hyperemic vasodilation [13], provid-
ing further evidence against a physiological role for
constrictions.
This dominant vasodilatory effect of astrocyte Ca2+ signaling
in vivo called into question the practical significance of the
astrocyte- and 20-HETE-mediated constrictions observed in
brain slices. Some clarification came from studies showing
that both vasodilation and vasoconstriction are possible,
depending on the conditions employed [5,14]. One such
study found that the polarity of astrocyte vasomotor influence
is dependent on pre-existing smooth-muscle tone [14]. In
isolated retinas, vasodilations dependent on astrocyte meta-
bolism of arachidonic acid by cytochrome (CYP) P450 2C11
(epoxygenase) to epoxyeicosatrienoic acids (EETs) became
less likely as NO levels increased and directly inhibited
epoxygenase activity [5]. This identified NO as a pro-
constriction factor despite its well-known actions as a direct
cGMP-dependent vasodilator [5,15]. These results could
explain discrepancies between earlier observations of
vasodilations, in the presence of a NOS inhibitor [2], and
vasoconstrictions, in conditions of no pre-constriction that
probably included higher endogenous NO levels [7]. An
opposite pro-dilatory effect of NO has also been observed
owing to NO-mediated inhibition of CYP P450 4A and 20-
HETE production [13] and it is not yet clear how these
effects of NO at CYP P450s are regulated.
The report by Gordon et al. [11] significantly improves our
understanding of the balance between vasoconstriction and
vasodilation in brain slices. They discovered that although the
mGluR-induced rise in astrocyte Ca2+ led to 20-HETE-
dependent vasoconstriction in slices maintained in high O2
(95%), the same treatment yielded PGE2-dependent vaso-
dilation in slightly hypoxic medium (20% O2). The mechanism
for this functional switch is twofold: first, mGluR activation
increased the rate of glycolysis in astrocytes, leading to
increased extracellular lactate levels sufficient to inhibit PGE2
reuptake via the PGE2/lactate exchanger (PGT). This resulted
in a net increase in extracellular PGE2 and a shift in the
vasomotor balance from vasoconstriction towards vasodila-
tion. Second, the authors postulate that the final tipping point
from dilation to constriction is the action of adenosine at
smooth muscle A2A receptors, which overrides the 20-HETE-
mediated constrictor effect. They showed that adenosine is
produced in low O2, that exogenous adenosine can block 20-
HETE-induced vasoconstriction at high (95%) O2, and that
mGluR-mediated vasoconstrictions can be converted to
dilations by adding exogenous adenosine and PGE2.
Overall, the findings of Gordon et al. [11] effectively
establish that astrocytes mediate bidirectional control of
local arteriolar diameter in a manner dictated by tissue
metabolic status. In this light, one can envisage a ‘see-saw’-
like balance between vasodilation and vasoconstriction with
weight for vasoconstriction provided by 20-HETE and
intracellular astrocyte NO, and weight on the vasodilation
end provided by adenosine, lactate and PGE2 and/or EETs.
It remains to be determined what fulcrum O2 level must be
reached before vasodilation is preferred. It is fairly certain
that this level is in the normoxic O2 range as in vivo
functional hyperemia paradigms at normal PO2 invariably
produce dilation and increased cerebral blood flow [3], and
the current findings by Gordon et al. [11] show that
vasodilation dominated near the low end of physiological
PO2 in brain slices. Determination of where the switch point
for dilation is may rest with characterizing how low PO2
must fall before ATP production is compromised and
adenosine accumulates. While Gordon et al. [11]
demonstrated adenosine production in the low physio-
logical range of PO2, it seems unlikely that slice PO2 in the
mid to high normoxic range (30-50 mmHg) would produce
enough adenosine to maintain dilatory efficacy. At this
point, one might predict that vasoconstriction would begin
to prevail. Alternatively, it remains possible that local
transient increases in extracellular adenosine resulting
from breakdown of extracellular ATP during neuro- or
gliotransmission could be sufficient to occupy A2A
receptors and drive vasodilation independent of a direct
effect of PO2. 
N Ne ew w   i id de ea as s   a ab bo ou ut t   ‘ ‘o ol ld d’ ’   v va as so od di il la at to or rs s
The paper by Gordon et al. [11] provides valuable hints about
how metabolic intermediates, including lactate, H+, K+ and
adenosine [9,16,17], might participate in a more regulated
and coordinated hyperemic response than would be allowed
simply by the diffusion of accumulated metabolites. The
authors show that lactate and adenosine, in particular,
participate in shifting the astrocyte vasomotor balance from
constriction to dilation.
Lactate has direct vasodilatory effects in vitro [17] and
augments increases in cerebral blood flow dependent on
neuronal activity [10], but Gordon et al. [11] have identified
a completely novel mechanism by which it can participate in
vasodilation. They confirm previous observations [18] that
mGluR activation drives astrocyte glycolysis and produces
lactate in low O2, and also show that preventing the con-
version of pyruvate to lactate eliminated mGluR-mediated
vasodilation in brain slices, making the first specific link
between astrocyte lactate and vasodilation. More impor-
tantly, they showed that the dilatory effects of lactate are
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extracellular lactate interferes with PGT-mediated exchange
of intracellular lactate for extracellular PGE2. These findings
establish lactate as a novel operator of the astrocyte
vasomotor switch and are consistent with the ability of
lactate to augment neuronal-activity-induced increases in
blood flow (modeled by Gordon et al. by using mGluR
activation) without affecting resting blood flow [10].
It should be noted that while the authors provide evidence
that mGluR-driven glycolysis in astrocytes is a source of
lactate that can inhibit PGT and enhance extracellular PGE2,
the contribution of astrocyte lactate produced by other
mechanisms may also be significant. For example, astrocyte
lactate can be derived from intracellular Na+ accumulated
during glutamate uptake [19]. A significant portion of the
hyperemic response in olfactory bulb was recently shown to
be dependent on glutamate transport, suggesting that this
pathway may represent an important source of lactate [4].
Glycogen mobilization also drives astrocyte lactate produc-
tion [20] but the contribution of this pathway is not known.
Adenosine acts as an inhibitory neuromodulator in the
central nervous system and is implicated in regulating
cerebral arterial tone in periods of increased neuronal activity
[21] and in hyperemia precipitated by hypoxia [22] and
hypoglycaemia [23]. There is also strong evidence for a direct
dilatory effect of adenosine at vascular A2A receptors during
hyperemia [24]. Gordon et al. [11]  showed that an A2A
receptor agonist blocked the mGluR-induced
vasoconstriction normally observed at 95% O2. They also
converted constrictions to dilations in the same high O2
conditions by combining exogenous adenosine with a PGT
blocker, which mimicked the increased PGE2 levels observed
during lactate production at lower O2 levels. These
observations support previous reports that A2A receptors are
vasodilatory in hyperemia and indicate that multiple
vasomotor effects are additive; in other words, A2A-mediated
dilation is capable of canceling 20-HETE-induced
vasoconstriction.
The experiments of Gordon et al. [11] raise at least three
intriguing questions on the role of adenosine in hyperemia.
First, the authors nicely demonstrate that exogenous adeno-
sine can compete with 20-HETE-mediated vasoconstriction
in conditions of high O2 but do not test whether endogenous
adenosine is required to yield dilations at 20% O2. It would
be interesting to investigate whether mGluR-mediated vaso-
dilation at 20% O2 is sensitive to inhibition by blocking the
effects of endogenous adenosine with an A2A receptor
antagonist or exogenous adenosine deaminase. The current
evidence leaves open the possibility that accumulation of
PGE2 by lactate-mediated inhibition of PGT is sufficient to
overcome the effects of 20-HETE and produce dilation
without endogenous adenosine. Second, while Gordon et al.
[11] undoubtedly show that A2A receptor effects can add to
the vascular effects of 20-HETE and PGE2, leading to
dilation, it remains to be seen whether other metabolic
vasodilators can contribute in the same additive way. It is
not yet known, for example, whether H+, K+ or the direct
vasodilatory effects of lactate itself can or do compete with
the effects of 20-HETE. Lastly, Gordon et al. [11] confirm the
widely held consensus that A2A adenosine receptors are
likely to play an important role in hyperemia. Given the
revelation that astrocyte A2B adenosine receptors regulate
EET production and neurovascular coupling in vivo [25], it
will be important to dissect the effects of endogenous
adenosine to determine whether adenosine acts both at
vascular A2A and astrocyte A2B receptors to influence the
vasomotor balance toward dilation.
The contribution of Gordon et al. [11] together with that of
Metea and Newman [5] show that previously identified
vasoactive mediators such as NO, adenosine and lactate may
converge on a central control point by influencing an
astrocyte-controlled vasomotor balance. The result is a clearer
view of the interplay among vasoactive effectors and a
conceptually tantalizing model of coordinated spatial cerebral
blood flow regulation by targeted vasodilations and
vasoconstrictions mediated by Ca2+ signal propagation in
distinct astrocyte networks.
A As st tr ro oc cy yt te es s   c co oo or rd di in na at te e   a a   m mu ul lt ti im mo od da al l   n nu ut tr ri it ti iv ve e   r re es sp po on ns se e
t to o   c ch ha al ll le en ng ge ed d   n ne eu ur ro on ns s
The findings that astrocyte vasomotor polarity depends on
oxygen-influenced changes in adenosine and activity-driven
extracellular lactate concentrations are novel and exciting
but do not exist in isolation. Rather, they are part of a
multifaceted response by astrocytes to neuronal energy
demand that also involves direct shuttling of tricarboxylic
acid (TCA) cycle carbon sources from astrocytes to neurons
(Figure 1). Perivascular astrocytes react in several ways to
glutamatergic signals from neurons. Glutamate released by
active neurons is rapidly removed from the synapse by high-
affinity astrocyte glutamate transporters [26] and the
internalized glutamate is converted to glutamine, which is
released by astrocytes and claimed by neurons. This enables
neurons to avoid a net loss of glutamate during neuro-
transmission and provides a potential TCA substrate for
synthesis of γ-aminobutyric acid and production of ATP.
Lactate is also shuttled from astrocytes to neurons for use as
an oxidative fuel. Lactate increases have been reported in
response to mGluR activation [18] and Na+-dependent
glutamate transporter activity [19], and lactate can also be
derived from mobilization of astrocyte glycogen in response
to neuronal activity [20,27]. Intracellular lactate is released
from astrocytes via the monocarboxylate transporter-1
(MCT1) where it can be taken up by neuronal MCT2 and
converted to pyruvate for use in the TCA cycle. Importantly,
astrocyte-neuron metabolic communication, and probably
vasomotor communication, cannot be viewed simply as
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groups of cells. New information affirms that lactate from
cerebral arterioles is delivered over large distances along
gap-junction-coupled astrocyte networks to areas of
stimulated neurons but not to resting neurons [28]. Overall,
astrocytes mount a multi-pronged neuronal aid effort
centered largely on the multiple vasomotor and metabolic
effects of lactate.
Studies over the past five years have revealed that astrocytes
link neuronal energy supply and demand by triggering
adaptive changes in the delivery of blood-borne glucose and
O2 to neurons. Gordon et al. [11] have taken the
understanding of this to a new level by showing that
astrocytes can act as switches to either increase or decrease
blood flow to working neurons depending on regional
metabolic status. Their study will serve as an important
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F Fi ig gu ur re e   1 1
Astrocyte influences on neuronal energy supply. Perivascular astrocytes respond to neuronal input (activity) by supplying neurons with substrates for
oxidative phosphorylation (lactate, glutamine (Gln)) and glutamate (Glu) replenishment (glutamine), and by signaling changes in local blood flow at the
vascular level. Active neurons produce synaptic glutamate that can be taken up by astrocyte glutamate transporters (EAAT) or activate mGluRs.
(1) EAAT activation drives electrogenic Na+ influx, activates Na+/K+ ATPases and stimulates glycolytic lactate generation. (2) mGluR activation also leads
to glycolysis and lactate production, and neuronal activity drives astrocyte glycogenolysis (3) and eventual lactate formation. Lactate from these three
sources is released to the extracellular space via monocarboxylate transporter 1 (MCT1) where it can be taken up by neuronal MCT2 and converted to
pyruvate (Pyr) for entry into the TCA cycle (4). Glutamate taken up by astrocyte EAATs can also be converted to glutamine by glutamine synthetase (5).
Glutamine can be released and taken up by neuronal amino acid transporters for re-synthesis of glutamate and/or γ-aminobutyric acid via the TCA cycle.
For astrocyte changes in blood flow, mGluR activation causes increased Ca2+ levels (6), leading to phospholipase A2 (PLA2) activation, arachidonic acid
(AA) formation (7) and vasoconstriction following 20-HETE production by cytochrome P450 ω-hydroxylase (8) and continuous prostaglandin E2 (PGE2)
generation by cyclooxygenase (COX) (9). Vasodilation can result in hypoxic conditions from lactate-mediated inhibition of PGE2 clearance by
prostaglandin transporters (PGT) following PGE2 diffusion to the vascular smooth muscle (10). EAAT, excitatory amino acid transporter; Pyr, pyruvate.
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PGE2launch point for future work aimed at identifying how
astrocyte networks regulate the spatial control of brain blood
flow both near to and distant from areas of neuronal
activation.
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